On February 23, 2026 Flatiron Health reported its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron’s real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A cornerstone of Flatiron’s presence at ASCO (Free ASCO Whitepaper) GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from over 420,000 relevant longitudinal patient records in Flatiron’s network. These prostate datasets specifically unlock high-quality, source-level unstructured and structured EHR data across Germany, the UK, and the US. Built on a common data model across all regions, these datasets enable unprecedented interoperability—allowing researchers to seamlessly analyze patient outcomes and treatment patterns across markets to inform global evidence strategies.

"Recent advancements have fundamentally transformed treatment options for genitourinary cancers, but our research reveals a critical gap: too many patients—particularly those with platinum-ineligibility, non-BRCA mutations, or comorbidities—are not benefiting from these breakthroughs," said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. "Our ASCO (Free ASCO Whitepaper) GU research, spanning disease states, biomarker status, and treatment types, illuminates how to translate innovation into practice. By capturing this real-world complexity at scale through our Panoramic Database, we’re generating the evidence needed to guide clinicians in a rapidly evolving treatment landscape—enabling them to deliver personalized medicine to any patient that is in front of them."

Research highlights include:

A study demonstrating the need for broader genetic testing and more equitable access to PARP inhibitors for all patients with DNA repair mutations, not just BRCAm carriers, to improve outcomes in advanced prostate cancer
A study suggesting that selected cisplatin-ineligible patients with muscle-invasive bladder cancer may benefit from chemotherapy despite medical limitations
A study revealing a critical need for more effective therapy options following Lu177, a treatment recently approved for metastatic castration-resistant prostate cancer
Join Flatiron Health at booth #26 Follow Flatiron Health on X and LinkedIn for more updates from #ASCOGU26.

Abstracts and Poster Presentations
Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations
Eunice A. Hankinson, Brendan T. Kerr, Patrick Ward, Khilna Patel, Samantha Reiss, Aaron Dolor, Michael Curry, Emily Castellanos
Abstract Number: 89
Poster Board Number: B22
Session Title: Poster Session A: Prostate Cancer
Date and Time: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)

Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)
Rana R. McKay, Weiyan Li, James Roose, Brendan T. Kerr, Smriti Karwa, Chinelo Orji, Nina Yeh, Theresa Cain, Jean H.E. Yong, Kumar Mukherjee
Author Affiliations: University of California San Diego, AstraZeneca, Merck & Co, Flatiron Health
Abstract Number: 102
Poster Board Number: C9
Session Title: Poster Session A: Prostate Cancer
Date and Time: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)

Treatment Patterns and Survival Outcomes Among Lutetium 177 – Experienced Patients with Metastatic Castration-Resistant Prostate Cancer
Ben Tran, Tanya Dorff, Madeline Richey, Eunice Hankinson, Patrick Olsen, Smriti Karwa, Jason Sharpe, Megan Braunlin, Christopher Kim
Author Affiliations: Peter Mac, City of Hope, Amgen, Flatiron Health
Abstract Number: 69
Poster Board Number: B2
Session Title: Poster Session A: Prostate Cancer
Date and Time: February 26, 2026, 11:30 AM-12:45 PM; 5:45 PM-6:45 PM (PST)

Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbidities
Enrique Grande, Aristotelis Bamias, Ronald de Wit, Syed Hussain, Constance Thibault, Mairead Kearney, Jason Hoffman, Valerie Morris, Li Chen, James Roose, Eunice Hankinson, Leonardo Crama, Julie Telliez, Joaquim Bellmunt
Author Affiliations: Quironsalud Madrid, National & Kapodistrian University of Athens, Erasmus MC Cancer Institute, University of Sheffield, Université Paris Cité, Merck KGaA, EMD Serono, Roche, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number: 666
Poster Board Number: C16
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)

Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment
Khilna Patel, Danni Zhao, Eunice Hankinson, Prakirthi Yerram, Aashay Mahesh Mehta, Emily Castellanos
Abstract Number: 672
Poster Board Number: C22
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)

Opportunities for Precision Oncology: Real-world Patterns and Disparities in FGFR3 Testing Among US Patients with Locally Advanced/Metastatic Urothelial Cancer (LA/mUC)
Emily Nash Smyth, Madeline Richey, Khilna Patel, Alan Brnabic, Nada Boualam, Sarah Reid, Ronac Mamtani
Author Affiliations: Eli Lilly and Company, Abramson Cancer Center, Flatiron Health
Abstract Number: 682
Poster Board Number: D6
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)

(Press release, Flatiron Health, FEB 23, 2026, View Source [SID1234662879])

On February 23, 2026 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, reported a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a poster session on February 28, 2026, at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancer Symposium.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Patients in the 100mg tablet cohort reached 15.1 months of PFS, and 45% had a confirmed response when treated with the same dose and formulation being used in the ongoing Phase 3 study," said Richard Markus, M.D., Ph.D., chief medical officer at Arcus Biosciences. "With longer follow-up, ORR continued to improve for both the 100mg QD cohort and pooled analysis, increasing meaningfully since the last analysis. Whether evaluating the pooled data or 100mg Phase 3 formulation data, PFS was two or nearly three times longer relative to published data from studies with the only marketed HIF-2a inhibitor in the same patient population."

ARC-20 is a Phase 1/1b dose-escalation and expansion study that included four monotherapy cohorts (n=121), which evaluated casdatifan in patients with metastatic ccRCC, most of whom had progressed on at least two prior lines of therapy, including both an anti-PD-1 and a VEGFR tyrosine kinase inhibitor (TKI): 50mg twice daily (BID), 50mg QD, 100mg QD (tablet) and 150mg QD. For biomarker analysis, serial serum samples were collected, and associations between maximal sEPO reduction and response to casdatifan were evaluated. These data showed that the magnitude and durability of EPO suppression correlated with clinical benefit, thereby linking pharmacodynamic modulation by casdatifan to clinical efficacy, including ORR and PFS.

"An analysis of data for casdatifan, a next-generation HIF-2a inhibitor, showed the majority of patients reached near-maximal sEPO reduction, and that deep and prolonged suppression was associated with better response and clinical benefit," said Toni K. Choueiri, M.D., director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber, the Jerome and Nancy Kohlberg chair and professor of medicine at Harvard Medical School, and lead investigator of ARC-20. "HIF-2a inhibition has emerged as a novel treatment that is changing the treatment paradigm for patients with ccRCC, and the results from ARC-20 are very encouraging. I look forward to working with Arcus to bring this medicine to ccRCC patients as soon as possible."

At the time of data cut-off (DCO, August 15, 2025), no unexpected safety signals were observed, and casdatifan had an acceptable and manageable safety profile across all doses. Across all four cohorts, no patients discontinued treatment due to anemia, and four patients (3%) discontinued due to hypoxia.

100mg QD Tablet

(Phase 3 dose)

(n=32)

Pooled Analysis

(50mg BID, 50mg QD, 100mg QD, 150mg QD)

(n=127)

Safetya

Any Serious Treatment-Emergent Adverse Events (TEAEs)

31% (10)

31% (39)

Grade ≥3 TEAEs related to casdatifanb

Anemia

25% (8)

41% (52)

Hypoxia

9% (3)

11% (14)

TEAEs resulting in discontinuation

9% (3)

9% (11)

Anemiac

0

0

Hypoxiac

3% (1)

2% (3)

a The safety-evaluable population included all dose-expansion enrolled patients who received any amount of any study treatment.

b Grade ≥3 TEAEs related to casdatifan that occurred in more than 5% of patients in the pooled analysis.

c Prespecified events of interest.

An updated analysis was conducted for efficacy with a DCO of January 30, 2026. The safety profile remained consistent with the August 15, 2025 DCO. Key differences between the August 15, 2025 and January 30, 2026 DCO are as follows:

100mg QD tablet cohort: At 17.9 months of median follow-up, cORR increased to 45% with an mPFS of 15.1 months. An mPFS had not yet been reached, and cORR was 35% at the August 15, 2025 DCO.
Pooled analysis: At 20.8 months of median follow-up, cORR increased to 35%, with three of the four monotherapy cohorts having cORRs greater than 30%, and mPFS was stable at 12.2 months; cORR was 31% at the August 15, 2025 DCO.

100mg QD Tablet

(Phase 3 dose)

(n=31)

Pooled Analysis

(50mg BID, 50mg QD, 100mg QD, 150mg QD)

(n=121)

Efficacya

Median Follow-Up

17.9 months

20.8 months

Median PFS

15.1 months

12.2 months

[95% CI]

[5.7,NE]

[9.4,16.5]

12-month PFS [95% CI]

61% [42,76]

51% [41,60]

6-month PFS [95% CI]

68% [48,81]

63% [54,71]

Confirmed ORR (cORR) [95% CI]

45% (14) [27,64]

35% (42) [26,44]

Confirmed BOR

CR

0

1% (1)

PR

45% (14)

34% (41)

SD

39% (12)

46% (56)

PDb,c

16% (5)

19% (23)

Median Time to Response

2.6 months

2.8 months

Disease Control Rate

84% (26)

81% (98)

[95% CI]

[66,95]

[73,88]

BOR: best overall response; CI: confidence interval; CR: complete response; NE: not estimable; PR: partial response; PD: progressive disease; SD: stable disease

a As of DCO of January 30, 2026; efficacy-evaluable population for this expansion cohort is defined as all eligible participants who received any study treatment and have at least one post-baseline efficacy assessment, or discontinued study treatment due to progressive disease or death.

b PD was defined according to RECIST v1.1 as a ≥ 20% increase in the sum of diameters of target lesions relative to the smallest sum on study (including baseline, if smallest), with an absolute increase of ≥ 5 mm. The appearance of 1 or more new lesions was also considered progression.

c Includes two patients in the 100mg QD tablet cohort, and also included in the pooled analysis, who had clinical progression before the first scan and therefore did not meet criteria for progressive disease per RECIST. PD based on RECIST criteria was 10% (n=3) for the 100mg QD tablet cohort and 17% (n=121).

About Casdatifan (AB521)

Casdatifan is a small-molecule inhibitor of HIF-2a, a master switch that turns on hundreds of genes in response to low oxygen levels. In a majority of people with the most common form of kidney cancer (clear cell renal cell carcinoma), genetic anomalies result in the dysregulation of this master switch and transformation of normal kidney cells into cancerous ones.

Casdatifan was designed to provide deep and durable inhibition of the HIF-2a pathway. Early clinical studies have shown high response rates and a low primary progression rate relative to clinical benchmarks, warranting further investigation in late-stage studies. Casdatifan, which is administered in pill form once daily, has a safety profile that allows it to be investigated in combination with other treatments.

Currently, fewer than one in four patients with late-line ccRCC respond to monotherapy treatment with a HIF-2a inhibitor, and a next-generation option, like casdatifan, may help more patients achieve benefit from HIF-2a-inhibitor treatment.

Casdatifan is an investigational molecule. Approval from any regulatory authority for its use has not been received, and its safety and efficacy have not been established. Taiho has development and commercial rights in Japan and other countries in Asia, excluding China. Arcus Biosciences holds full rights to casdatifan everywhere else globally.

About RCC

According to the American Cancer Society, kidney cancer is among the top 10 most commonly diagnosed forms of cancer among both men and women in the U.S., and an estimated 80,450 Americans will be diagnosed with kidney cancer in 2026. Clear cell RCC is the most common type of kidney cancer in adults. If detected in its early stages, the five-year survival rate for kidney cancer is high; for patients with advanced or late-stage metastatic kidney cancer, however, the five-year survival rate is only 19%. For metastatic kidney cancer, targeted drug therapies are one of the main treatment options.

(Press release, Arcus Biosciences, FEB 23, 2026, View Source [SID1234662878])

On February 23, 2026 Vir Biotechnology, Inc. (Nasdaq: VIR), reported a corporate update and announced financial results for the fourth quarter and full year ended December 31, 2025.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is a seminal moment for Vir Biotechnology, marked by key high-potential partnerships on two of our programs showcasing the strength of our pipeline and technology platforms. Today, we announced a global strategic collaboration with Astellas and compelling new Phase 1 data for VIR-5500, demonstrating the potential for our PRO-XTEN masked TCEs to play a transformative role in oncology and impact the lives of people living with hard-to-treat cancers," said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. "Additionally, our licensing agreement with Norgine signed in December 2025, for the combination of tobevibart and elebsiran for the treatment of hepatitis delta, positions us to reach patients worldwide who face hepatitis delta, the most severe form of chronic viral hepatitis. Together, these milestones reflect how we are unlocking meaningful value in our pipeline and expanding the reach of our potential therapies."

Pipeline Programs

Chronic Hepatitis Delta (CHD)

To support global commercialization of the combination of tobevibart, an investigational neutralizing monoclonal antibody (mAb), and elebsiran, an investigational small interfering RNA (siRNA), for the treatment of CHD, the Company granted Norgine Pharma UK Limited (Norgine) an exclusive commercial license in Europe, Australia and New Zealand.
Phase 2 SOLSTICE data presented at the 44ᵗʰ Annual J.P. Morgan Healthcare Conference in January 2026 showed the combination of tobevibart and elebsiran is well tolerated and achieved undetectable hepatitis delta virus RNA (HDV RNA Target Not Detected, TND) in 88% (21/24) of participants with CHD evaluable at Week 96 of treatment.
Previous positive Phase 2 SOLSTICE data at Week 48 were presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025 and simultaneously published in the New England Journal of Medicine.1
Topline data from the ECLIPSE 1 trial are expected in the fourth quarter of 2026. Topline data from the ECLIPSE 2 and ECLIPSE 3 trials are expected in the first quarter of 2027.
Solid Tumors

VIR-5500

The Company executed a global strategic collaboration with Astellas2 to advance PSMA-targeted PRO-XTEN dual-masked TCE VIR-5500, currently in development for metastatic castration-resistant prostate cancer (mCRPC).
Positive updated Phase 1 data for VIR-5500 monotherapy showed dose-dependent anti-tumor activity and a well-tolerated safety profile to date in patients with mCRPC. The data will be shared during the Company’s fourth quarter and full year conference call today and in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium on February 26 (Oral Abstract #17). The oral presentation will be delivered by Dr. Johann de Bono, Principal Investigator and Director of the Drug Development Unit and Head of Prostate Cancer Targeted Therapy Group at the Institute of Cancer Research.
Phase 1 monotherapy dose-escalation of weekly and once every three weeks dosing of VIR-5500 is complete, and the Company has defined a preliminary go-forward dose and regimen recommendation for expansion. In parallel, dose-escalation of VIR-5500 in combination with enzalutamide continues in early-line mCRPC patients.
The Company anticipates initiating monotherapy dose-expansion cohorts in late-line mCRPC and combination dose-expansion cohorts in both early-line mCRPC and metastatic hormone-sensitive prostate cancer (mHSPC) in the second quarter of 2026 followed by pivotal Phase 3 trials in 2027.
VIR-5818

Phase 1 dose-escalation of VIR-5818, a HER2-targeted PRO-XTEN dual-masked TCE, in combination with pembrolizumab continues, with response data expected in the second half of 2026.
VIR-5525

The Phase 1 study of VIR-5525, an EGFR-targeted PRO-XTEN dual-masked TCE, continues enrollment as expected.
Preclinical Pipeline Candidates

The Company is currently progressing a number of PRO-XTEN masked TCEs in preclinical studies directed at clinically validated targets with potential applications across a variety of solid tumors, including lung, colorectal and bladder.
Fourth Quarter and Full Year 2025 Financial Results

Cash, Cash Equivalents and Investments: As of December 31, 2025, the Company had approximately $781.6 million in cash, cash equivalents and investments, representing a decline of approximately $29.1 million during the fourth quarter of 2025. For the full year of 2025, cash, cash equivalents and investments declined approximately $313.8 million. During the fourth quarter, the Company received a $64.3 million initial cost reimbursement payment upon signing the license agreement with Norgine.

Revenue: Revenue for the fourth quarter of 2025 was $64.1 million compared to $12.4 million for the same period in 2024. Revenue for the full year of 2025 was $68.6 million compared to $74.2 million in 2024. The increase in the fourth quarter was primarily driven by the recognition of $64.3 million license revenue related to the initial cost reimbursement payment received under the license agreement with Norgine. The decrease in the full year was primarily due to lower license and collaboration revenue from GSK and lower grant revenue, partially offset by the license revenue recognized under the license agreement with Norgine.

Cost of Revenue: The change in cost of revenue for the fourth quarter and full year of 2025 compared to the same periods in 2024 was nominal.

Research and Development (R&D) Expenses: R&D expenses for the fourth quarter of 2025 were $88.3 million, which included $5.6 million of non-cash stock-based compensation expense, compared to $106.1 million for the same period in 2024, which included $8.3 million of non-cash stock-based compensation expense. R&D expenses for the full year of 2025 were $456.0 million, which included $25.1 million of non-cash stock-based compensation expense, compared to $506.5 million in 2024, which included $43.9 million of non-cash stock-based compensation expense. The decrease in both the fourth quarter and full year was primarily due to cost savings from previously announced restructuring initiatives as well as lower expenses from contingent consideration liability revaluation, partially offset by higher clinical cost due to the initiation of our Phase 3 ECLIPSE registrational program and progression of our oncology programs.

The full year of 2025 R&D expenses include a $75.0 million milestone payment made upon VIR-5525 achieving first-in-human dosing, the $30.0 million expense in connection with amending the Company’s license agreement with Alnylam Pharmaceuticals, Inc., and milestone payments due upon initiation of the ECLIPSE Phase 3 registrational program. These 2025 license-related expenses were substantially offset by the $102.8 million upfront license payment made to Sanofi in 2024.

Selling, General and Administrative (SG&A) Expenses: SG&A expenses for the fourth quarter of 2025 were $23.6 million, which included $5.6 million of non-cash stock-based compensation expense, compared to $26.7 million for the same period in 2024, which included $7.5 million of non-cash stock-based compensation expense. SG&A expenses for the full year of 2025 were $92.1 million, which included $24.0 million of non-cash stock-based compensation expense, compared to $119.0 million in 2024, which included $34.5 million of non-cash stock-based compensation expense. The decrease in both the fourth quarter and the full year was primarily due to efficiencies and cost savings from previously announced restructuring initiatives.

Restructuring, Long-Lived Assets Impairment and Related Charges: The decrease in restructuring, long-lived assets impairment and related charges for the fourth quarter and full year of 2025 was due to the fact that our restructuring initiatives implemented in prior years were substantially completed by the end of 2024.

Other Income: The decrease in other income for the fourth quarter and full year of 2025 was primarily driven by lower interest income. Additionally, the decrease in the full year was partially offset by lower unrealized loss from the Company’s equity investment.

Benefit from (Provision for) Income Taxes: The change in benefit from (provision for) income taxes for the fourth quarter and the full year of 2025 was nominal.

Net Loss: Net loss attributable to Vir Biotechnology for the fourth quarter of 2025 was $(42.9) million, or $(0.31) per share, basic and diluted, compared to a net loss of $(104.6) million, or $(0.76) per share, basic and diluted, for the same period in 2024. Net loss attributable to Vir Biotechnology for the year of 2025 was $(438.0) million, or $(3.16) per share, basic and diluted, compared to a net loss of $(522.0) million, or $(3.83) per share, basic and diluted, in 2024.

2026 Financial Guidance

Based on current operating plans, including the expected net effects of the Astellas global collaboration and the Astellas equity investment,2 the Company expects its cash, cash equivalents and investments to fund operations into the second quarter of 2028.

Conference Call

Vir Biotechnology will host its fourth quarter and full year 2025 financial results conference call at 5:30 p.m. ET / 2:30 p.m. PT today, when members of the executive team and Dr. de Bono will share the updated VIR-5500 Phase 1 data that is also being presented at the 2026 ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium on February 26. A live webcast will be available at View Source and will be archived for 30 days.

(Press release, Vir Biotechnology, FEB 23, 2026, View Source [SID1234662877])

On February 23, 2026 IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, reported the completion of its last patients’ five-year follow up evaluation in its ICESECRET clinical trial of ProSense for the treatment of small renal masses ("SRMs") in kidney cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ICESECRET, a prospective, multicenter, single-arm clinical trial, was performed at Bnai Zion Medical Center in Haifa, Israel and Shamir Medical Center in Be’er Ya’akov, Israel and is led by Principal Investigator Prof. Halahmi Sarel. The trial included 114 patients (138 lesions) with localized SRMs of ≤5 cm ablated with ProSense cryoablation under CT guidance. Follow-up visits were performed at six weeks, six months, one year and then annually up to five years after the procedure using ProSense. During follow-up visits, data related to local recurrence, based on CT imaging, was collected. Safety was determined by monitoring procedure-related adverse events throughout the study.

"Interim three-year data from ICESECRET, which was collected from 111 eligible patients at the time, was presented a year ago and demonstrated the strong potential of ProSense cryoablation as a safe and effective option for patients who are otherwise ineligible for kidney preserving surgery, a growing unmet need," stated Eyal Shamir, IceCure’s Chief Executive Officer. "Importantly, ProSense already has regulatory approval to treat kidney cancer in key markets including the U.S. and Europe. We are now working closely with Prof. Sarel on data analysis and publication, with the intention of bringing this minimally invasive procedure to patients in Israel with kidney cancer."

SRMs are increasingly detected due to widespread imaging and represent a growing clinical challenge, particularly among elderly patients and those with comorbidities who are not suitable candidates for surgery. Minimally invasive, nephron-sparing treatment options that preserve kidney function, while effectively controlling tumors, are critically needed.

About ProSense

The ProSense Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company’s website.

ProSense is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.

ProSense enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense opens the door to fast and convenient office-based procedures for breast tumors.

(Press release, IceCure Medical, FEB 23, 2026, View Source [SID1234662876])

On February 23, 2026 TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, reported the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Director of the Precision Health Program, and Associate Dean for Research Development at the College of Human Medicine at Michigan State University and scientific co-founder of TransCode.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data describe a template-driven RIG-I agonist strategy to selectively activate retinoic acid-inducible gene I (RIG-I) signaling inside tumor cells by leveraging overexpressed oncogenic microRNAs, such as miRNA-21, as intracellular assembly templates. This approach directly addresses longstanding challenges associated with RIG-I agonists, including off-target immune activation and inefficient systemic delivery.

"Our findings demonstrate a novel approach to precisely engage innate immune pathways directly within tumor cells, while minimizing systemic toxicity," said Zdravka Medarova, Ph.D., CSO of TransCode. "We believe that combining tumor-specific RNA templating with our TTX nanoparticle delivery platform brings RIG-I-based immunotherapy closer to clinical relevance." TransCode’s TTX delivery platform is currently being evaluated in clinical trials, underscoring the translational feasibility of this immunotherapy approach.

Molecular Imaging and Biology is a peer-reviewed scientific journal and the official publication of the World Molecular Imaging Society, focused on translational research in molecular imaging and image-guided therapies with clinical and commercial relevance.

(Press release, TransCode Therapeutics, FEB 23, 2026, View Source [SID1234662875])